UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection

Journal of virology, 2015-12, Vol.89 (23), p.11884-11898

2015

Volltextzugriff (PDF)

Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex

PLoS pathogens, 2014-11, Vol.10 (11), p.e1004524-e1004524

2014

Volltextzugriff (PDF)

Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice

Journal of virology, 2018-10, Vol.92 (19)

2018

Volltextzugriff (PDF)

A Vaccine Based on the Rhesus Cytomegalovirus UL128 Complex Induces Broadly Neutralizing Antibodies in Rhesus Macaques

Journal of Virology, 2013-02, Vol.87 (3), p.1322-1332

2013

Volltextzugriff (PDF)

Identification of a Continuous Neutralizing Epitope within UL128 of Human Cytomegalovirus

Journal of virology, 2017-03, Vol.91 (6)

2017

Volltextzugriff (PDF)

Protection against Congenital CMV Infection Conferred by MVA-Vectored Subunit Vaccines Extends to a Second Pregnancy after Maternal Challenge with a Heterologous, Novel Strain Variant

Viruses, 2021-12, Vol.13 (12), p.2551

2021

Volltextzugriff (PDF)

COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants

iScience, 2022-06, Vol.25 (6), p.104457-104457, Article 104457

2022

Volltextzugriff (PDF)

Open Reading Frames Carried on UL/b′ Are Implicated in Shedding and Horizontal Transmission of Rhesus Cytomegalovirus in Rhesus Monkeys

Journal of Virology, 2011-05, Vol.85 (10), p.5105-5114

2011

Volltextzugriff (PDF)

Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants

iScience, 2022-08, Vol.25 (8), p.104745-104745, Article 104745

2022

Volltextzugriff (PDF)

Vaccine-Induced Control of Viral Shedding following Rhesus Cytomegalovirus Challenge in Rhesus Macaques

Journal of Virology, 2011-03, Vol.85 (6), p.2878-2890

2011

Volltextzugriff (PDF)

The immune response to human CMV

Future Virology, 2012-03, Vol.7 (3), p.279-293

2012

Volltextzugriff (PDF)

Patterns of Acute Rhesus Cytomegalovirus (RhCMV) Infection Predict Long-Term RhCMV Infection

Journal of Virology, 2012-06, Vol.86 (11), p.6354-6357

2012

Volltextzugriff (PDF)

Recombinant Modified Vaccinia Virus Ankara Expressing a Soluble Form of Glycoprotein B Causes Durable Immunity and Neutralizing Antibodies against Multiple Strains of Human Cytomegalovirus

Journal of Virology, 2004-04, Vol.78 (8), p.3965-3976

2004

Volltextzugriff (PDF)

Cytomegalovirus-vectored vaccines for HIV and other pathogens

AIDS (London), 2020-03, Vol.34 (3), p.335-349

2020

Volltextzugriff (PDF)

The susceptibility of primary cultured rhesus macaque kidney epithelial cells to rhesus cytomegalovirus strains

Journal of general virology, 2016-06, Vol.97 (6), p.1426-1438

2016

Volltextzugriff (PDF)

Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques

Medical microbiology and immunology, 2008-06, Vol.197 (2), p.117-123

2008

Volltextzugriff (PDF)

Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex

Journal of virological methods, 2018-01, Vol.251, p.30-37

2018

Volltextzugriff (PDF)

Development of a novel, guinea pig-specific IFN-γ ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine

Vaccine, 2014-06, Vol.32 (31), p.3963-3970

2014

Volltextzugriff (PDF)

Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses

Virology (New York, N.Y.), 2010-08, Vol.403 (2), p.155-162

2010

Volltextzugriff (PDF)

Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1

Vaccine, 2007-01, Vol.25 (6), p.1132-1141

2007

Volltextzugriff (PDF)

Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition

Vaccine, 2005-05, Vol.23 (26), p.3453-3468

2005

Volltextzugriff (PDF)

Cross-reactive CTL recognizing two HLA-A02-restricted epitopes within the BK virus and JC virus VP1 polypeptides are frequent in immunocompetent individuals

Virology (New York, N.Y.), 2006-06, Vol.350 (1), p.128-136

2006

Volltextzugriff (PDF)

Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection

Journal of clinical virology, 2006-03, Vol.35 (3), p.324-331

2006

Volltextzugriff (PDF)

DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A0201 mice

Vaccine, 2004-12, Vol.23 (6), p.819-826

2004

Volltextzugriff (PDF)

Site-directed mutation in a conserved kinase domain of human cytomegalovirus-pp65 with preservation of cytotoxic T lymphocyte targeting

Vaccine, 2001-02, Vol.19 (13), p.1628-1635

2001

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieThe Journal Of Infectious Diseases

ThemaVirology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)
Japanisch
(7)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection

Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex

Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice

A Vaccine Based on the Rhesus Cytomegalovirus UL128 Complex Induces Broadly Neutralizing Antibodies in Rhesus Macaques

Identification of a Continuous Neutralizing Epitope within UL128 of Human Cytomegalovirus

Protection against Congenital CMV Infection Conferred by MVA-Vectored Subunit Vaccines Extends to a Second Pregnancy after Maternal Challenge with a Heterologous, Novel Strain Variant

COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants

Open Reading Frames Carried on UL/b′ Are Implicated in Shedding and Horizontal Transmission of Rhesus Cytomegalovirus in Rhesus Monkeys

Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants

Vaccine-Induced Control of Viral Shedding following Rhesus Cytomegalovirus Challenge in Rhesus Macaques

The immune response to human CMV

Patterns of Acute Rhesus Cytomegalovirus (RhCMV) Infection Predict Long-Term RhCMV Infection

Recombinant Modified Vaccinia Virus Ankara Expressing a Soluble Form of Glycoprotein B Causes Durable Immunity and Neutralizing Antibodies against Multiple Strains of Human Cytomegalovirus

Cytomegalovirus-vectored vaccines for HIV and other pathogens

The susceptibility of primary cultured rhesus macaque kidney epithelial cells to rhesus cytomegalovirus strains

Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques

Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex

Development of a novel, guinea pig-specific IFN-γ ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine

Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses

Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1

Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition

Cross-reactive CTL recognizing two HLA-A02-restricted epitopes within the BK virus and JC virus VP1 polypeptides are frequent in immunocompetent individuals

Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection

DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A0201 mice

Site-directed mutation in a conserved kinase domain of human cytomegalovirus-pp65 with preservation of cytotoxic T lymphocyte targeting

Aktive Filter

Suchergebnisse filtern